PT  - JOURNAL ARTICLE
AU  - Bin Wang
AU  - Li Wang
AU  - Xianggen Kong
AU  - Jin Geng
AU  - Di Xiao
AU  - Chunhong Ma
AU  - Xue-Mei Jiang
AU  - Pei-Hui Wang
TI  - Long-term Coexistence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with Antibody Response in Coronavirus Disease 2019 (COVID-19) Patients
AID  - 10.1101/2020.04.13.20040980
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.13.20040980
4099  - http://medrxiv.org/content/early/2020/04/17/2020.04.13.20040980.short
4100  - http://medrxiv.org/content/early/2020/04/17/2020.04.13.20040980.full
AB  - Severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019 has spread worldwide. Whether antibodies are important for the adaptive immune responses against SARS-CoV-2 infection needs to be determined. Here, 26 cases of COVID-19 in Jinan, China, were examined and shown to be mild or with common clinical symptoms and no cases of severe symptoms were found among these patients. A striking feature of some patients is that SARS-CoV-2 could exist in patients who have virus-specific IgG antibodies for a very long period, with one case for up to 36 days. One COVID-19 patient who did not produce any SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness, revealing that without antibody-mediated adaptive immunity, innate immunity may still be powerful enough to eliminate SARS-CoV-2. Overall, this report may provide a basis for further analysis of both innate and adaptive immunity in SARS-CoV-2 clearance, especially in non-severe cases. This study also has implications for understanding the pathogenesis and treatment of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from COVID-19 emergency tackling research project of Shandong University (Grant No. 2020XGB03 to P.-H.W).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available.